BioLineRx Files 6-K, Issues Press Release on Feb 16
Ticker: BLRX · Form: 6-K · Filed: Feb 16, 2024 · CIK: 1498403
Sentiment: neutral
Topics: regulatory-filing, press-release
TL;DR
**BioLineRx just filed a 6-K, meaning they dropped a press release today, February 16, 2024, so keep an eye out for news!**
AI Summary
BioLineRx Ltd. filed a Form 6-K on February 16, 2024, indicating it issued a press release on the same date. This filing, under Commission file number 001-35223, reports on events required for foreign private issuers under the Securities Exchange Act of 1934. The company, based in Modi'in, Israel, continues to file annual reports under Form 20-F.
Why It Matters
This filing signals that BioLineRx has new information for investors, likely related to its pharmaceutical operations, which could impact its stock performance.
Risk Assessment
Risk Level: low — This 6-K filing is a routine disclosure of a press release and does not inherently indicate a high risk event.
Key Players & Entities
- BioLineRx Ltd. (company) — registrant
- February 16, 2024 (date) — date of press release and filing
- 001-35223 (other) — Commission file number
- Modi'in 7177871, Israel (location) — principal executive offices
FAQ
What is the purpose of BioLineRx Ltd.'s 6-K filing on February 16, 2024?
The purpose of BioLineRx Ltd.'s 6-K filing on February 16, 2024, is to report that the registrant issued a press release on the same date, which is filed as Exhibit 1 to this Report on Form 6-K.
Under which form does BioLineRx Ltd. file its annual reports?
BioLineRx Ltd. files its annual reports under Form 20-F, as indicated by the checked box in the filing.
What is the Commission file number for BioLineRx Ltd.?
The Commission file number for BioLineRx Ltd. is 001-35223.
Where are BioLineRx Ltd.'s principal executive offices located?
BioLineRx Ltd.'s principal executive offices are located at 2 HaMa'ayan Street, Modi'in 7177871, Israel.
What is the accession number for this specific 6-K filing?
The accession number for this specific 6-K filing is 0001178913-24-000626.
Filing Stats: 150 words · 1 min read · ~1 pages · Grade level 10.3 · Accepted 2024-02-16 07:07:06
Filing Documents
- zk2431005.htm (6-K) — 9KB
- exhibit_1.htm (EX-99) — 31KB
- image00001.jpg (GRAPHIC) — 109KB
- 0001178913-24-000626.txt ( ) — 191KB
From the Filing
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant's name into English) 2 HaMa'ayan Street Modi'in 7177871, Israel (Address of Principal Executive Offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F Form 40-F On February 16, 2024, the registrant issued the press release which is filed as Exhibit 1 to this Report on Form 6-K. Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BioLineRx Ltd. By: /s/ Philip A. Serlin Philip A. Serlin Chief Executive Officer Dated: February 16, 2024